Company intelligence / Profile preview

Tempo Therapeutics

San Diego, California, United Statestempothera.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

Tempo Therapeutics has enrolled 40 patients in first-in-human clinical trials for TT101, its leading pipeline candidate for skin cancer surgical reconstruction. The company is on track to begin pivotal clinical trials in 2026 and estimates an FDA submission in late 2027. Preclinical data from 30 real-world veterinary cases demonstrated significant improvements in surgical reconstruction and tissue regeneration[6].

Therapeutic areas: OtherDermatology
Modalities: Synthetic tissue scaffoldsMaterial science technologyCellular therapies
Industry: Surgical Medical Devices

Drug pipeline

2 assets

TT101

Phase 1

Indications: Complex surgical sites with exposed bone, tendon, or fascia

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tempo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tempo Therapeutics.

Explore the full profile